Treatment of cells with TGFα was conducted to ensure that the lack of EpCAM reduction following activation of EGFR through EGF was not due to requirements for different EGFR ligands in HNSCC cell lines. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.